These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19458885)

  • 61. Association of clinical variables and polymorphisms in RANKL, RANK, and OPG genes with external apical root resorption.
    Borges de Castilhos B; Machado de Souza C; Simas Netta Fontana MLS; Pereira FA; Tanaka OM; Trevilatto PC
    Am J Orthod Dentofacial Orthop; 2019 Apr; 155(4):529-542. PubMed ID: 30935608
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.
    Ermakov S; Trofimov S; Malkin I; Livshits G
    Osteoporos Int; 2012 Jul; 23(7):1899-907. PubMed ID: 22057548
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association between Genetic Polymorphisms in RANK, RANKL and OPG and Peri-Implant Diseases in Patients from the Amazon Region.
    Silva RCE; Reis MBL; Arid J; Flores EKB; Cruz GV; Marañón-Vásquez GA; Souza LKF; Novaes AB; Queiroz AM; Küchler EC
    Braz Dent J; 2020; 31(1):63-68. PubMed ID: 32159708
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
    Wang J; Gao H; Wang K; Li W; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Jul; 23(7):777-80. PubMed ID: 19662974
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Effect of Osteoprotectin (OPG)/Receptor Activator of Nuclear Factor-
    Luo W; Song Y; Wang J; Yang X; Li Z; Cong H
    Biomed Res Int; 2022; 2022():1592576. PubMed ID: 35993046
    [TBL] [Abstract][Full Text] [Related]  

  • 67. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women.
    Mencej-Bedrač S; Preželj J; Marc J
    Maturitas; 2011 Jul; 69(3):263-7. PubMed ID: 21411255
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Analyses of RANK and RANKL in the post-GWAS context: functional evidence of vitamin D stimulation through a RANKL distal region.
    Yoskovitz G; Garcia-Giralt N; Rodriguez-Sanz M; Urreizti R; Guerri R; Ariño-Ballester S; Prieto-Alhambra D; Mellibovsky L; Grinberg D; Nogues X; Balcells S; Diez-Perez A
    J Bone Miner Res; 2013 Dec; 28(12):2550-60. PubMed ID: 23744843
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of technetium-99 conjugated with methylene diphosphonate (
    Shen S; Wang W; Yang C; Xu B; Zeng L; Qian Y
    J Oral Pathol Med; 2019 Feb; 48(2):129-135. PubMed ID: 30421571
    [TBL] [Abstract][Full Text] [Related]  

  • 71. OPG and RANKL polymorphisms are associated with alcohol-induced osteonecrosis of the femoral head in the north area of China population in men.
    Li Y; Wang Y; Guo Y; Wang Q; Ouyang Y; Cao Y; Jin T; Wang J
    Medicine (Baltimore); 2016 Jun; 95(25):e3981. PubMed ID: 27336899
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma.
    Łacina P; Butrym A; Humiński M; Dratwa M; Frontkiewicz D; Mazur G; Bogunia-Kubik K
    Mol Carcinog; 2021 Feb; 60(2):106-112. PubMed ID: 33283899
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation.
    Cao H; Wang J; Xi L; Røe OD; Chen Y; Wang D
    Circ J; 2011; 75(12):2781-8. PubMed ID: 22001292
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosis.
    Wolski H; Drews K; Bogacz A; Kamiński A; Barlik M; Bartkowiak-Wieczorek J; Klejewski A; Ożarowski M; Majchrzycki M; Seremak-Mrozikiewicz A
    Ginekol Pol; 2016; 87(5):347-52. PubMed ID: 27304650
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
    J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Multiple genetic loci for bone mineral density and fractures.
    Styrkarsdottir U; Halldorsson BV; Gretarsdottir S; Gudbjartsson DF; Walters GB; Ingvarsson T; Jonsdottir T; Saemundsdottir J; Center JR; Nguyen TV; Bagger Y; Gulcher JR; Eisman JA; Christiansen C; Sigurdsson G; Kong A; Thorsteinsdottir U; Stefansson K
    N Engl J Med; 2008 May; 358(22):2355-65. PubMed ID: 18445777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. OPG/RANKL/RANK gene methylation among alcohol-induced femoral head necrosis in northern Chinese men.
    Wang T; Wang F; Liu T; Sun M; An F; Liu C; Tian Y; Cao Y; Wang J
    J Orthop Surg Res; 2021 Mar; 16(1):223. PubMed ID: 33773583
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids.
    Atilano-Miguel S; Barbosa-Cortés L; Ortiz-Muñiz R
    Bol Med Hosp Infant Mex; 2022; 79(5):275-283. PubMed ID: 36264895
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
    Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.